OCULAR THERAPEUTIX, INC Payments to Acquire Debt Securities, Available-for-sale
OCULAR THERAPEUTIX, INC (OCUL) reported Payments to Acquire Debt Securities, Available-for-sale of $3.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-03-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2020-03-12
- OCULAR THERAPEUTIX, INC payments to acquire debt securities, available-for-sale for the quarter ending 2016-12-31 was $27.70M, a 66.13% increase year-over-year.
- OCULAR THERAPEUTIX, INC payments to acquire debt securities, available-for-sale for the quarter ending 2016-09-30 was $2.50M, a 95.65% decline year-over-year.
- OCULAR THERAPEUTIX, INC payments to acquire debt securities, available-for-sale for the quarter ending 2015-12-31 was $16.67M.
- OCULAR THERAPEUTIX, INC payments to acquire debt securities, available-for-sale for the quarter ending 2015-09-30 was $57.51M.
- OCULAR THERAPEUTIX, INC payments to acquire debt securities, available-for-sale for fiscal 2017 was $3.00M, a 92.81% decline from fiscal 2016.
- OCULAR THERAPEUTIX, INC payments to acquire debt securities, available-for-sale for fiscal 2016 was $41.70M, a 54.52% decline from fiscal 2015.
- OCULAR THERAPEUTIX, INC payments to acquire debt securities, available-for-sale for fiscal 2015 was $91.68M, a 145.63% increase from fiscal 2014.
- OCULAR THERAPEUTIX, INC payments to acquire debt securities, available-for-sale for fiscal 2014 was $37.33M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2017-12-31 | $3.00M 10-K · filed 2020-03-12 | |||
| 2016-12-31 | $27.70M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $30.20M derived: sum of 2 quarters · filed 2019-03-07 | $41.70M 10-K · filed 2019-03-07 | |
| 2016-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $14.00M 10-Q · filed 2016-11-09 | ||
| 2016-06-30 | $11.50M 10-Q · filed 2016-08-09 | |||
| 2015-12-31 | $16.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $74.18M derived: sum of 2 quarters · filed 2018-03-08 | $74.18M derived: sum of 3 quarters · filed 2018-03-08 | $91.68M 10-K · filed 2018-03-08 |
| 2015-09-30 | $57.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $57.51M derived: sum of 2 quarters · filed 2016-11-09 | $75.01M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $17.50M 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $17.50M 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $37.33M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |